Milestone Payment — In-Licensed Drug Compound
Recording a development milestone payment to a licensor when an in-licensed compound achieves Phase II proof-of-concept.
| Account Name | Type | Debit ($) | Credit ($) |
|---|---|---|---|
| R&D Expense — In-License Milestone | Expense (+) | 25,000,000.00 | - |
| Milestone Payable / Cash | Liability/Asset (-) | - | 25,000,000.00 |
💡 Accountant's Note
Development milestone payments in pharmaceutical in-licensing agreements are typically expensed as R&D when the triggering event occurs (e.g., Phase II completion, regulatory submission). Since the compound has not yet been approved, it does not meet the IAS 38 asset recognition criteria — future revenue is still highly uncertain.
Practitioner & Systems Framework
💻 ERP Architecture
Milestone payments are tracked in the licensing management system (or a contract management module) alongside the full licensing agreement. When the triggering milestone is achieved, the clinical/regulatory team notifies finance, triggering the payment and expense recognition. The payment is processed through AP after invoice receipt from the licensor. For milestone payments that are contingent on regulatory approval (NDA/BLA/MAA acceptance or approval), the payment may be capitalised as an intangible asset (the approved drug's IP) if the approval creates a reliably measurable asset — this is a significant accounting judgement applied at approval, not during development.
⚠️ Audit Flags
Auditors confirm the milestone triggering event has genuinely occurred and review the supporting documentation (clinical data readout, regulatory acceptance letter). Test the R&D expense vs. capitalisation classification — pre-approval milestones are expensed; post-approval milestones (for approved indications) may be capitalised. For milestone payments triggered by regulatory approval, assess whether the payment meets the IAS 38 criteria for intangible asset recognition at that point. Review the licensing agreement for any additional contingent milestones and assess whether they constitute contingent liabilities requiring IAS 37 disclosure.
📄 Required Documentation
Licensing agreement (milestone schedule and triggering conditions), milestone achievement evidence (clinical trial results, regulatory correspondence), licensor invoice, AP payment record, IAS 38 / IAS 37 accounting assessment (expense vs. capitalise), and remaining contingent milestone schedule disclosure.
Professional Excel Template
Get the automated version of this entry. Includes built-in IFRS checks, VAT calculators, and SAP-ready upload formats.
Expert Analysis by Qusai Ahmad
General Accountant Supervisor & IFRS Specialist
Specialized in SAP GUI automation and Middle Eastern tax compliance. Building digital tools for the next generation of finance leaders.